Alzheon secures $100m to advance Alzheimer’s disease treatment

2024-06-13

交易

临床2期临床3期申请上市

Alzheon secures $100m to advance Alzheimer’s disease treatment

Preview

来源: Pharmaceutical Technology

The asset demonstrated clinical efficacy in the highest-risk AD population and favourable safety. Credit: PRPicturesProduction / Shutterstock.

Clinical-stage biopharmaceutical company Alzheon has secured $100m in a Series E funding round to develop and commercialise ALZ-801/Valiltramiprosate, an oral tablet designed as a disease-modifying therapy for Alzheimer’s disease (AD).

Recommended Buyer's Guides

Preview

来源: Pharmaceutical Technology

Buyer's Guide

Leading Guide to Compliance Software for the Pharmaceutical Industry

Preview

来源: Pharmaceutical Technology

Buyer's Guide

Leading Guide to Clinical Packaging Companies in contract Manufacturing for the Pharmaceutical Industry

Alerce Medical Technology Partners spearheaded the financing round.

The development comes after the company raised $50m in a Series D round in 2022.

The investment will be used to complete the APOLLOE4 Phase III clinical trial to evaluate the efficacy of ALZ-801 in 325 early AD patients.

The study will report its results in the third quarter of 2024, with a new drug application (NDA) submission to follow.

See Also:NPX-267 by NextPoint Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Preview

来源: Pharmaceutical Technology

PF-07960613 by Pfizer for Respiratory Syncytial Virus (RSV) Infections: Likelihood of Approval

Preview

来源: Pharmaceutical Technology

ALZ-801 inhibits the formation of soluble toxic amyloid aggregates, acting upstream from all late-stage amyloid-targeting treatments.

The financial boost will also support the manufacture of the product and prepare for the potential launch of ALZ-801 commercially, as the first oral disease-modifying therapy for Alzheimer’s.

ALZ-801 has demonstrated the ability to fully block the formation of neurotoxic soluble beta-amyloid oligomers at the Phase III clinical dose level.

It also demonstrated clinical efficacy in the highest-risk AD population and favourable safety, without causing higher brain vasogenic oedema risk.

ALZ-801 was also evaluated in a two-year, 84-patient, Phase II biomarker study completed in the second half of 2023.

The biomarker trial is now extending into a fourth year.

Alzheon founder, president and CEO Martin Tolar stated: “Alzheon has experienced tremendous progress in the past year and the promise of our novel oral Alzheimer’s treatment, ALZ-801, has attracted prominent institutional and private investors.

“Our ability to raise $150m over the last two financing rounds in the current climate speaks volumes about the prospects of our innovative science and technology.

“Our well-differentiated drug candidate with a favourable safety profile, showing no increased risk of vasogenic brain oedema in more than 3,000 AD patients, is positioned to potentially become the first oral disease-modifying therapy for the treatment of Alzheimer’s disease.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构